These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29396328)

  • 1. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy.
    Koyasu H; Goshima S; Noda Y; Nishibori H; Takeuchi M; Matsunaga K; Yamada T; Matsuo M
    Jpn J Radiol; 2019 Jan; 37(1):81-87. PubMed ID: 30392134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Sasada S; Shiroma N; Goda N; Kajitani K; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Breast Cancer Res Treat; 2019 Oct; 177(3):651-657. PubMed ID: 31267329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors.
    Sasada S; Kimura Y; Masumoto N; Emi A; Kadoya T; Arihiro K; Okada M
    Eur J Surg Oncol; 2021 Jul; 47(7):1588-1592. PubMed ID: 33685728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
    Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Masumoto N; Kadoya T; Sasada S; Emi A; Arihiro K; Okada M
    Breast Cancer Res Treat; 2018 Sep; 171(2):315-323. PubMed ID: 29779072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
    Tokuda Y; Yanagawa M; Fujita Y; Honma K; Tanei T; Shimoda M; Miyake T; Naoi Y; Kim SJ; Shimazu K; Hamada S; Tomiyama N
    Breast Cancer Res Treat; 2021 Jul; 188(1):107-115. PubMed ID: 33730265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of dedicated breast positron emission tomography.
    Hashimoto R; Akashi-Tanaka S; Watanabe C; Masuda H; Taruno K; Takamaru T; Ide Y; Kuwayama T; Kobayashi Y; Takimoto M; Nakamura S
    Breast Cancer; 2022 Nov; 29(6):1013-1021. PubMed ID: 35768684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer.
    Sakaguchi R; Kataoka M; Kanao S; Miyake KK; Nakamoto Y; Sugie T; Toi M; Mikami Y; Togashi K
    Ann Nucl Med; 2019 Aug; 33(8):570-578. PubMed ID: 31115856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer.
    Sueoka S; Sasada S; Masumoto N; Emi A; Kadoya T; Okada M
    Breast Cancer Res Treat; 2021 May; 187(1):125-133. PubMed ID: 33484374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
    Hathi DK; Li W; Seo Y; Flavell RR; Kornak J; Franc BL; Joe BN; Esserman LJ; Hylton NM; Jones EF
    Sci Rep; 2020 Dec; 10(1):21930. PubMed ID: 33318514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
    Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
    Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
    Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study.
    Satoh Y; Motosugi U; Imai M; Onishi H
    Ann Nucl Med; 2020 Feb; 34(2):119-127. PubMed ID: 31768819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.